StockData
Bluejay Diagnostics, Inc. logo

Bluejay Diagnostics, Inc. (BJDX) stock

BJDXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$2.15−0.14 (-5.90%)

Close on Nov 17, 2026Market cap $9.63MP/E –Yield –

Bluejay Diagnostics r&d expenses

Research and development expenses are spending on new products and technology.

Bluejay Diagnostics's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.62M, up 30.2% year over year. For fiscal 2025 it was $3.05M, down 12.2% from the year before. The highest annual figure on record is $5.71M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.05M-12.2%
FY2024Dec 31, 2024$3.47M-39.2%
FY2023Dec 31, 2023$5.71M+37.6%
FY2022Dec 31, 2022$4.15M+261.7%
FY2021Dec 31, 2021$1.15M+117.7%
FY2020Dec 31, 2020$527.25K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.44M+61.6%
Q1 FY2026Mar 31, 2026$811.84K+3.4%
Q4 FY2025Dec 31, 2025$586.14K+5.8%
Q3 FY2025Sep 30, 2025$785.61K+42.4%
Q2 FY2025Jun 30, 2025$889.90K-13.8%
Q1 FY2025Mar 31, 2025$784.80K-41.2%
Q4 FY2024Dec 31, 2024$554.00K-56.9%
Q3 FY2024Sep 30, 2024$551.66K-60.5%
Q2 FY2024Jun 30, 2024$1.03M-38.4%
Q1 FY2024Mar 31, 2024$1.33M-1.5%
Q4 FY2023Dec 31, 2023$1.29M-2.6%
Q3 FY2023Sep 30, 2023$1.40M+1.3%
Q2 FY2023Jun 30, 2023$1.68M+121.6%
Q1 FY2023Mar 31, 2023$1.35M+95.0%
Q4 FY2022Dec 31, 2022$1.32M+190.3%
Q3 FY2022Sep 30, 2022$1.38M+211.8%
Q2 FY2022Jun 30, 2022$756.28K+234.7%
Q1 FY2022Mar 31, 2022$694.76K+2772.9%
Q4 FY2021Dec 31, 2021$455.25K+8.6%
Q3 FY2021Sep 30, 2021$442.53K+16151.5%
Q2 FY2021Jun 30, 2021$225.99K–
Q1 FY2021Mar 31, 2021$24.18K–
Q4 FY2020Dec 31, 2020$419.06K–
Q3 FY2020Sep 30, 2020$2.72K–

More Bluejay Diagnostics figures

See a number that looks wrong?